# Tripegfilgrastim Trial to Reduce the Risk of Severe Neutropenia in Patients With Unresectable Pancreaticobiliary Cancers

> **NCT06135896** · PHASE2 · RECRUITING · sponsor: **National Cancer Center, Korea** · enrollment: 98 (estimated)

## Conditions studied

- Unresectable Pancreatic Cancer
- Unresectable Bile Duct Carcinoma
- Unresectable Biliary Tract Carcinoma

## Interventions

- **DRUG:** Tripegfilgrastim

## Key facts

- **NCT ID:** NCT06135896
- **Lead sponsor:** National Cancer Center, Korea
- **Sponsor class:** OTHER_GOV
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-01-16
- **Primary completion:** 2026-06-30
- **Final completion:** 2026-06-30
- **Target enrollment:** 98 (ESTIMATED)
- **Last updated:** 2025-06-18

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06135896

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06135896, "Tripegfilgrastim Trial to Reduce the Risk of Severe Neutropenia in Patients With Unresectable Pancreaticobiliary Cancers". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT06135896. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*